Center for Nano Science and Technology @PoliMi, Istituto Italiano di Tecnologia, Via Pascoli 70/3, 20133 Milano, Italy.
Computational Sciences, Istituto Italiano di Tecnologia, via Morego 30, 16163 Genova, Italy.
Int J Mol Sci. 2019 Jul 11;20(14):3404. doi: 10.3390/ijms20143404.
Cadherins are a large family of transmembrane calcium-dependent cell adhesion proteins that orchestrate adherens junction formation and are crucially involved in tissue morphogenesis. Due to their important role in cancer development and metastasis, cadherins can be considered attractive targets for drug discovery. A recent crystal structure of the complex of a cadherin extracellular portion and a small molecule inhibitor allowed the identification of a druggable interface, thus providing a viable strategy for the design of cadherin dimerization modulators. Here, we report on a structure-based virtual screening approach that led to the identification of efficient and selective modulators of E-cadherin-mediated cell-cell adhesion. Of all the putative inhibitors that were identified and experimentally tested by cell adhesion assays using human pancreatic tumor BxPC-3 cells expressing both E-cadherin and P-cadherin, two compounds turned out to be effective in inhibiting stable cell-cell adhesion at micromolar concentrations. Moreover, at the same concentrations, one of them also showed anti-invasive properties in cell invasion assays. These results will allow further development of novel and selective cadherin-mediated cell-cell adhesion modulators for the treatment of a variety of cadherin-expressing solid tumors and for improving the efficiency of drug delivery across biological barriers.
钙黏蛋白是一大类跨膜钙依赖性细胞黏附蛋白,它们协调黏着连接的形成,并且在组织形态发生中起着至关重要的作用。由于钙黏蛋白在癌症发展和转移中的重要作用,它们可以被认为是药物发现的有吸引力的靶点。最近,钙黏蛋白外部分子与小分子抑制剂复合物的晶体结构的确定,确定了一个可成药的界面,从而为设计钙黏蛋白二聚体调节剂提供了可行的策略。在这里,我们报告了一种基于结构的虚拟筛选方法,该方法导致了鉴定有效和选择性的 E-钙黏蛋白介导的细胞-细胞黏附调节剂。在通过表达 E-钙黏蛋白和 P-钙黏蛋白的人胰腺肿瘤 BxPC-3 细胞的细胞黏附测定实验中,对所有鉴定出的假定抑制剂进行了测试,其中两种化合物在微摩尔浓度下有效地抑制稳定的细胞-细胞黏附。此外,在相同浓度下,其中一种化合物在细胞侵袭测定中也表现出抗侵袭特性。这些结果将允许进一步开发新型和选择性的钙黏蛋白介导的细胞-细胞黏附调节剂,用于治疗各种表达钙黏蛋白的实体瘤,并提高穿过生物屏障的药物输送效率。